FIG. 1



Study Design Schema
IMGN632 Dose Escalation Phase
MTD Expansion Cohorts
IMGN632 administered on D1 of a 21-day cycle R/R AML or BPDCN (n=3-6/cohort)*
CRC review
Schedule A: IMGN632 administered on D1 of a 21-day cycle R/R AML or BPDCN (n=3-6/cohort)*
Schedule B: IMGN632 administered on an alternate dosing schedule (D1, 4**, and 8 of a 21-day cycle) R/R AML or BPDCN (n=3-6/cohort)*
MTD
MTD
Data review to select dose(s)/ schedule(s) for expansion (RP2D[s])**
Cohort 1: CD123+ relapsed/ refractory BDPCN (n=50)
Cohort 2: CD123+ relapsed AML (n=20)
Cohort 3: CD123+ relapsed ALL (n=20)
Cohort 4: CD123+ relapsed other hematologic malignancies (n=20)
Cohort 5: CD123+ relapsed AML at alternate dose or schedule (n=20)

FIG. 2



IMGN632-0801 Best Response
Best % decrease in BM blasts
100%
50%
0%
-50%
-100%
Clinical PD
BPDCN 84% to 5%
AML 46% to 2%
MRD <0.1% hypocellular
PD
SD
PR
CR/CRi

FIG. 3



CD123 levels in IMGN632-0801 Patients
CD123+ Leukemic cells %
100
80
60
40
20
0
0
20
40
60
80
100
120
140
CD123 Expression (MFI)
CR/Cri
Stable Disease
Progressive Disease
No data

FIG. 4




CD123 Receptor Saturation Average
Cohort 1 (0.015 mg/kg)
Cohort 2 (0.045 mg/kg)
Cohort 3 (0.09 mg/kg)
Cohort 4 (0.18 mg/kg)
Cohort 5 (0.30 mg/kg)
Cohort 6 (0.45 mg/kg)
Percent
100
50
0
0
1
2
3 6
8
10
12
14
Days Post Injection

FIG. 5


0.015 mg/kg
0.045 mg/kg
0.090 mg/kg
0.18 mg/kg
0.3 mg/kg
0.45 mg/kg
10000
1000
100
10
1
0
1
2
3
Time (days)
IMGN632 Concentration
(ng/mL)



Chemical Structure
G4723A
1.5-2.1
sulfonated-DGN549-C
Note: The sulfur adjacent to the G4723A antibody is derived from the site specific engineered cysteine residues on the antibody

FIG. 6A



G4723A
1.5-2.1
corresponding mono-imine

FIG. 6B